Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Stock Has Consensus Target Price of $4.00

Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) have earned an average recommendation of “Hold” from the seven analysts that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $4.00.

HOWL has been the topic of a number of recent analyst reports. Wall Street Zen raised Werewolf Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. Weiss Ratings raised Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 10th.

Insider Activity at Werewolf Therapeutics

In related news, Director Luke Evnin sold 107,429 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $0.31, for a total value of $33,302.99. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 23.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Werewolf Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in HOWL. Bank of America Corp DE acquired a new position in Werewolf Therapeutics during the second quarter worth about $112,000. Squarepoint Ops LLC acquired a new stake in shares of Werewolf Therapeutics in the second quarter valued at approximately $37,000. Finally, BlackRock Inc. acquired a new stake in shares of Werewolf Therapeutics in the second quarter valued at approximately $37,000. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

Werewolf Therapeutics Stock Performance

HOWL stock opened at $0.93 on Wednesday. The stock has a market capitalization of $45.11 million, a PE ratio of -1.22 and a beta of 0.51. The company has a fifty day moving average of $0.75 and a 200-day moving average of $0.64. Werewolf Therapeutics has a one year low of $0.27 and a one year high of $2.15.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Friday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.36. The firm had revenue of $21.00 million for the quarter, compared to analyst estimates of $21.00 million. Equities analysts forecast that Werewolf Therapeutics will post -0.89 earnings per share for the current fiscal year.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies. The company uses its proprietary INDUKINE platform to design conditionally activated cytokines, which are intended to stimulate the immune system within the tumor microenvironment while limiting activity in healthy tissues.

Werewolf’s pipeline has included WTX-124, an investigational interleukin-2 therapy designed to promote the expansion and activation of immune cells in tumors, and WTX-330, an investigational interleukin-12 therapy intended to activate both innate and adaptive immune responses.